AbbVie’s Maviret achieves 96% cure rate for acute hepatitis C but excludes key patient groups, raising access and efficacy concerns in real-world…
Compass Pathways has filed an FDA NDA for its psilocybin depression treatment, COMP360, after two Phase 3 trials…
Proteolysis-targeting chimeras face major formulation hurdles that may delay their approval. Learn about the challenges facing PROTAC drugs…
Insilico Medicine’s AI-designed TEAD inhibitor ISM6331 shows 18.2% response rate in mesothelioma patients, with 68.2% achieving disease control…
AbbVie’s Maviret achieves 96% cure rate for acute hepatitis C but excludes key patient groups, raising access and…
Moderna and Merck are seeking approval for intismeran autogene, a melanoma vaccine, after their November 6 earnings release,…
Trump pressures Europe to cut drug prices, while his administration delays new launches, as a March 2026 poll…
FDA approves Voceryq, the first DNA-based immunotherapy for HPV-driven recurrent respiratory papillomatosis (RRP), offering hope for patients avoiding…
Generic manufacturers may shift focus to reliability due to supply chain issues and price pressure affecting the industry.
Fresenius expands biosimilars portfolio through big deal with WuXi Biologics, gaining option rights on up to 37 candidates.
Germany's AfD softens anti euro stance ahead of national government hopes. Explore the party's strategic shift and political…
